Cargando…
Molecular docking analysis of MCL-1 inhibitors for breast cancer management
Myeloid leukemia 1 (MCL-1), a BCL-2 protein family member, acts as an anti-apoptotic protein by interacting with pro-apoptotic BCL-2 proteins. Its overexpression is frequently observed in numerous cancer types including breast cancer, and is closely linked to the initiation and progression of tumors...
Autores principales: | Abdulrahman, Alzahrani, Mohammad Azhar, Kamal, Asif Hussain, Akber, Ali Abdullah, Asiri, Marui, Ibrahim Shafei, Mohammed Hadi, Ghawi, Hanan Mamdouh, Alotaibi, Qamre, Alam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Biomedical Informatics
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598365/ https://www.ncbi.nlm.nih.gov/pubmed/37885779 http://dx.doi.org/10.6026/97320630019707 |
Ejemplares similares
-
Molecular docking analysis of KRAS inhibitors for cancer management
por: J. Hakeem, Israa, et al.
Publicado: (2023) -
Molecular docking analysis of HER-2 inhibitor from the ZINC database as anticancer agents
por: Sait, Khalid Hussain Wali, et al.
Publicado: (2020) -
From sequence analysis of DPP-4 to molecular docking based searching of its inhibitors
por: Alsamghan, Awad Saeed, et al.
Publicado: (2020) -
Insights from the molecular docking analysis of EGFR antagonists
por: Kamal, Mohammad Azhar, et al.
Publicado: (2023) -
Structure-based virtual screening and molecular docking for the identification of potential novel EGFRkinase inhibitors against ovarian cancer
por: Sait, Khalid Hussain Wali, et al.
Publicado: (2019)